Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data ...

加利福尼亚州FOSTER CITY - 专注于开发肿瘤和肥胖症治疗方法的生物制药公司Terns Pharmaceuticals, Inc. (NASDAQ:TERN)今天宣布计划通过公开发行普通股和预付认股权证筹集1.25亿美元。该公司还计划向承销商提供30天期权,以购买价值高达1875万美元的额外股份。

Terns的首席医疗官Emil Kuriakose表示：“我们对TERN-601的强效GLP-1受体激动作用感到非常兴奋，其独特的药物特性允许通过每日一次给药实现持续的靶向覆盖，并且我们已经能够评估高达740毫克的剂量，同时保持良好的耐受性。”公司计划在2025年将该药物推进至第二阶段的临床试验。

周一，Jefferies将Terns Pharmaceuticals (NASDAQ:TERN)的股票目标价从之前的22.00美元上调至30.00美元，同时维持买入评级。此次调整是基于TERN-601的1期临床试验结果，该结果显示出令人鼓舞的成果，符合分析师的乐观预期。

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining ...

FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

Terns Pharmaceuticals (TERN.US)的每日一次GLP-1受体激动剂TERN-601在早期临床试验中展现了治疗肥胖症的积极效果。在一项为期28天的多次递增剂量试验中，TERN-601显示出良好的耐受性，并且在所有三个剂量水平 ...

Terns Pharmaceuticals this morning reported that its small molecule GLP-1 pill led to weight loss in a short Phase 1 study, ...

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study. Read my thoughts on this weight loss ...

Terns intends to use the net proceeds from the proposed offering to fund research, clinical trials, development and manufacturing of the Company’s key product candidates, including TERN-701, TERN-601 ...